Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

摘要: Anti-anaplastic lymphoma kinase (ALK)-targeted therapy dramatically improves therapeutic responses in patients with ALK-rearranged lung adenocarcinoma (Ad-LC). A few cases of squamous cell carcinoma (Sq-LC) ALK rearrangement have been reported; however, the clinicopathological features and clinical outcomes following treatment inhibitors are unknown. We addressed this present study by retrospectively comparing characteristics five Sq-LC those Ad-LC evaluating representative inhibitor responders non-responders. The prevalence Sq-LCs was 1.36%. Progression-free survival (PFS) after initial crizotinib significantly shorter than (p = 0.033). Two rearrangements assayed fluorescence situ hybridization (FISH)-positive/immunohistochemistry-negative did not respond to crizotinb, PFS decreased alectinib 0.045). rebiopsy revealed that ceritinib harbored L1196M mutation, which causes resistance other inhibitors. However, non-responders were resistant all inhibitors, despite presence FISH-positive circulating tumor cells free DNA absence mutation. These results indicate remain a reasonable option for who worse mechanisms heterogeneous. Additionally, oncologists should be aware possibility based on features, plan second-line strategies order improve patient outcome.